Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6989270 | 0.87 | ALDH1A1 (0.51) | CES1CES2AKR1B1L3MBTL1ALDH1A1 | |
| SCHEMBL6987142 | 0.87 | CES2 (0.52) | CES1CES2MEN1KMT2AL3MBTL1 | |
| SCHEMBL29271945 | 0.84 | L3MBTL1 (0.50) | CES1CES2TSHRMEN1KMT2A | |
| SCHEMBL26638162 | 0.84 | FNTA (0.55) | CES2MEN1KMT2AMAPTFNTA | |
| SCHEMBL335504 | 0.79 | LTA4H (0.57) | CES1CES2L3MBTL1MAPTTDP1 | |
| SCHEMBL354299 | 0.79 | NPC1 (0.50) | TSHRMEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL9595063 | 0.79 | PLAU (0.58) | CES1CES2MEN1KMT2AL3MBTL1 | |
| SCHEMBL10489992 | 0.78 | CES1 (0.52) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL8672567 | 0.78 | CES1 (0.52) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL2322710 | 0.78 | CES1 (0.52) | CES1CES2AKR1B1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300183-A | Spiropyran derivative, optical/electric double-response membrane material and preparation method thereof | 中国石油化工股份有限公司 | 2021-02-02 | — | — | CN | claimed |
| JP-4838934-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1185239-B1 | PRO-FRAGRANCES | PROCTER & GAMBLE (US) | 2010-03-10 | — | — | EP | claimed |
| EP-1569935-B1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREOF AND USE OF SAME AS MEDICAMENTS, SUCH AS ANTI-BACTERIAL MEDICAMENTS AND BETA-LACTAMASE INHIBITORS | NOVEXEL (FR) | 2008-08-20 | — | — | EP | claimed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | claimed |
| EP-1042291-B1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2005-07-13 | — | — | EP | claimed |
| US-6861402-B1 | Pro-fragrances | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-01 | — | — | US | claimed |
| EP-1171566-B1 | PRO-FRAGRANCES | PROCTER & GAMBLE (US) | 2004-12-22 | — | — | EP | claimed |
| US-20040067870-A1 | Fragrance raw materials aldehydes and pro-fragrances having a tertiary alpha carbon atom | THE PROCTER & GAMBLE COMPANY | 2004-04-08 | — | — | US | claimed |
| US-6551987-B1 | For delivering fragrance raw material ketones, preferably alpha , beta -unsaturated ketones, inter alia, damascones, ionones to human skins | THE PROCTER & GAMBLE COMPANY | 2003-04-22 | — | — | US | claimed |
| EP-0882059-B1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES | LYNX THERAPEUTICS INC (US) | 2002-02-06 | — | — | EP | claimed |
| EP-1171566-A1 | PRO-FRAGRANCES | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-16 | — | — | EP | claimed |
| WO-2000063339-A1 | PRO-FRAGRANCES | THE PROCTER & GAMBLE COMPANY (US) | 2000-10-26 | — | — | WO | claimed |
| EP-1042291-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| WO-1999031064-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| CN-1056878-A | 2-substituted alkyl-3-carboxycarbapenems as antibiotics and process for their preparation | AMERICAN CYANAMID CO (US) | 1991-12-11 | — | — | CN | claimed |
| US-4643849-A | ANTIULCER, ANTISECRETORY AGENTS | TOYAMA CHEMICAL CO., LTD. (JP) | 1987-02-17 | — | — | US | claimed |
| EP-0053072-A1 | Oxacephalosporins and their preparation | RHONE-POULENC SANTE (FR) | 1982-06-02 | — | — | EP | claimed |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-3952105-A | TRIORGANO-STANNOXY SUBSTITUTED 6B METAL ESTER | SCM CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067870-A1 | Fragrance raw materials aldehydes and pro-fragrances having a tertiary alpha carbon atom | CUTA, TRPA1, HRH1 | CES1 798/4885CES2 239/4885AKR1B1 1085/4885 |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | CYP7A1, UGT1A3, UGT1A1 | CES1 246/4885CES2 753/4885AKR1B1 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.